November 20, 2024
OncoSpherix Becomes a Portal Innovations Member Company
Atlanta, GA – Nov 2023 – OncoSpherix,, Inc., a preclinical-stage cancer drug development company advancing HIF inhibitors for a variety of cancer indications, is excited to announce its recent relocation to facilities managed by Portal Innovations, a prominent venture capital firm dedicated to supporting life sciences innovation. The move marks a significant step forward for OncoSpherix, as the company joins a dynamic ecosystem that offers critical resources to accelerate its research and development efforts.
Portal Innovations’ facilities provide fully equipped lab space and a supportive community designed to help promising life sciences companies achieve their goals. With seed capital, expertise, and introductions to strategic partners and investors, Portal Innovations is uniquely positioned to empower OncoSpherix’s mission of transforming cancer treatment and advancing its pipeline of innovative therapies.
“We’re thrilled to be part of Portal Innovations’ network and look forward to leveraging this environment to drive our next phase of growth,” said OncoSpherix CEO, Margaret Offermann, MD, PhD. “Access to state-of-the-art lab facilities and strategic support will enable us to expand our R&D capabilities and progress in our goal to make a meaningful impact on the lives of patients.”
Portal Innovations specializes in helping exceptional life sciences innovators build their companies where they live, surrounding them with resources such as seed capital, fully equipped lab spaces, and connections to other investors and partners. By joining Portal Innovations, OncoSpherix gains access to these invaluable resources, bolstering its efforts to address some of the most challenging needs in oncology.
With its new location, OncoSpherix is positioned for accelerated innovation and enhanced collaboration, reinforcing its commitment to advancing next-generation cancer therapies. For more information about OncoSpherix’s work, visit http://www.oncospherix.com/.
About OncoSpherix:
OncoSpherix, Inc., based in Atlanta, Ga, is a pre-clinical stage oncology drug development company that is advancing a proprietary platform of first-in-class small molecule therapeutics that are designed to improve the quality of life and survival for people with many forms of cancer by targeting a common feature of solid tumors: the activation of hypoxia inducible factor-1 (HIF-1). Nearly all solid cancers grow faster than their blood supplies, leading to regions of low oxygen in the tumors and HIF activation. The HIFs in turn induce the expression of over 100 genes that help tumor cells survive and spread. OncoSpherix has several classes of small molecules that block activation of HIF-1 through novel mechanisms. OncoSpherix’s lead clinical candidate has been shown in mouse models to reduce primary tumor growth, inhibit metastasis, and prolong survival in many types of cancer (glioblastoma, pancreatic cancer, uveal melanoma, lung cancer, breast cancer). OncoSpherix intends to advance its lead candidate in one or more of these indications, in combination with agents that show therapeutic synergy while being well-tolerated.as part of the combination.
Company Contact:
Allan Valmonte
VP of Business Operations
Source: OncoSpherix, Inc.